Download

Audience for the document: Share Class: Language of the document:

Download

Share Class: Language of the document:

Change Details

If you need to change your email address please contact us.
Subscriptions
OK
You are ready to start subscribing.
Get started by going to our products or insights section to follow what you're interested in.

Products Insights

GIPS® Information

T. Rowe Price ("TRP") claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS standards. T. Rowe Price has been independently verified for the twenty four-year period ended June 30, 2020, by KPMG LLP. The verification report is available upon request. A firm that claims compliance with the GIPS standards must establish policies and procedures for complying with all the applicable requirements of the GIPS standards. Verification provides assurance on whether the firm’s policies and procedures related to composite and pooled fund maintenance, as well as the calculation, presentation, and distribution of performance, have been designed in compliance with the GIPS standards and have been implemented on a firm-wide basis. Verification does not provide assurance on the accuracy of any specific performance report.

TRP is a U.S. investment management firm with various investment advisers registered with the U.S. Securities and Exchange Commission, the U.K. Financial Conduct Authority, and other regulatory bodies in various countries and holds itself out as such to potential clients for GIPS purposes. TRP further defines itself under GIPS as a discretionary investment manager providing services primarily to institutional clients with regard to various mandates, which include U.S, international, and global strategies but excluding the services of the Private Asset Management group.

A complete list and description of all of the Firm's composites and/or a presentation that adheres to the GIPS® standards are available upon request. Additional information regarding the firm's policies and procedures for calculating and reporting performance results is available upon request

Other Literature

You have successfully subscribed.

Notify me by email when
regular data and commentary is available
exceptional commentary is available
new articles become available

Thank you for your continued interest

Please enter valid search characters

Expanding Opportunities in China

June 2022 / EMERGING MARKETS EQUITY

Are the Clouds Set to Clear for Chinese Equities

Are the Clouds Set to Clear for Chinese Equities

Are the Clouds Set to Clear for Chinese Equities

Embracing uncertainty and inefficiencies to focus on future drivers of growth.

By Wenli Zheng

Wenli Zheng Regional Portfolio Manager

June 2022 / EMERGING MARKETS

The Case for China Remains Strong

The Case for China Remains Strong

The Case for China Remains Strong

A more complex environment does not necessarily mean a less rewarding one.

By Justin Thomson

Justin Thomson Head of International Equity

March 2022 / EMERGING MARKETS EQUITY

Making Sense of the Sell-Off, Then Rally in Chinese ADRs

Making Sense of the Sell-Off, Then Rally in Chinese ADRs

Making Sense of the Sell-Off, Then Rally...

Concerns about delistings on U.S. exchanges appear to be overblown.

January 2022 / EMERGING MARKETS

China Unexplored

China Unexplored

China Unexplored

By Charles Knudsen

Charles Knudsen Portfolio Specialist

February 2022 / INTERNATIONAL EQUITIES

China Deleveraging: Domestic and Global Impacts

China Deleveraging: Domestic and Global Impacts

China Deleveraging: Domestic and Global Impacts

A multiyear path to reduce financial risk and improve credit allocation.

By Christopher J. Kushlis

Christopher J. Kushlis Asia Sovereign Analyst, London

January 2022 / EMERGING MARKETS

China Unexplored

China Unexplored

China Unexplored

By Charles Knudsen

Charles Knudsen Portfolio Specialist

October 2021 / EMERGING MARKETS

China: Too Big to Ignore

China: Too Big to Ignore

China: Too Big to Ignore

Insights Webinar Summary

By Christopher J. Kushlis & Wenli Zheng

By Christopher J. Kushlis & Wenli Zheng

September 2021 / FIXED INCOME

Controlled Deflation of the China Property Debt Balloon

Controlled Deflation of the China Property Debt Balloon

Controlled Deflation of the China Property...

Beijing’s policy actions in the property sector seem to be containing any potential...

By Sheldon Chan & Anna Zhang

By Sheldon Chan & Anna Zhang

June 2021 / EMERGING MARKETS

Constructing a Chinese Equities Portfolio

Constructing a Chinese Equities Portfolio

Constructing a Chinese Equities Portfolio

Seek to exploit market inefficiencies and extract value from entire investment universe.

By Irmak Surenkok

Irmak Surenkok Portfolio Specialist

China Evolution Equity Strategy

The strategy seeks to identify mispriced companies with opportunities driven by change. We scour the full spectrum of Chinese equity markets—A-shares, H-shares, and U.S. Listed ADRs—in pursuit of the most compelling risk/reward prospects.

China Evolution Equity Composite Strategy Highlight

May 2022 / INTERNATIONAL EQUITIES

China Is an Outlier in a COVID-Accepting World

China Is an Outlier in a COVID-Accepting World

China Is an Outlier in a COVID-Accepting...

Beijing remains cautious about a near-term policy shift.

By Christopher J. Kushlis

Christopher J. Kushlis Chief of China and Emerging Markets Macro Strategy

February 2022 / EMERGING MARKETS

Meet Jackie Liu

Meet Jackie Liu

Meet Jackie Liu

By Jacqueline Liu

Jacqueline Liu Portfolio Manager, China Growth Opportunities Equity Strategy

December 2021 / INTERNATIONAL EQUITIES

China Market Outlook 2022

China Market Outlook 2022

China Market Outlook 2022

Attractive opportunities amid China’s fast‑changing environment.

By Wenli Zheng

Wenli Zheng Portfolio Manager, China Evolution Equity Portfolio

December 2021 / VIDEO

Video Series – China: Too Big to Ignore

Video Series – China: Too Big to Ignore

Video Series – China: Too Big to Ignore

By Wenli Zheng & Christopher J. Kushlis

By Wenli Zheng & Christopher J. Kushlis

September 2021 / FIXED INCOME

Regulatory Actions in China: Short-Term Pain, Long-Term Gain

Regulatory Actions in China: Short-Term Pain, Long-Term Gain

Regulatory Actions in China: Short-Term Pain,...

Beijing’s tightening grip bodes well for China Inc.'s health.

By Sheldon Chan, Christopher J. Kushlis & Lee Sun

By Sheldon Chan, Christopher J. Kushlis & Lee Sun

August 2021 / MARKET EVENTS

China Regulation—Opportunity May Lie in the Midst of Stock Sell-Off

China Regulation—Opportunity May Lie in the Midst of Stock Sell-Off

China Regulation—Opportunity May Lie in the...

We are assessing potential winners and losers amid new regulations in the education...

By Multiple Authors

By Multiple Authors

June 2021 / INTERNATIONAL EQUITIES

Gains Still to Be Found in Chinese Equities

Gains Still to Be Found in Chinese Equities

Gains Still to Be Found in Chinese Equities

Corporate earnings will likely be the focus after a post‑pandemic recovery.

By Wenli Zheng

Wenli Zheng Regional Portfolio Manager